Centenial Surgical Suture Ltd Surges 20.49%: Key Financial Turnaround and Technical Shifts

1 hour ago

Share Via

Centenial Surgical Suture Ltd delivered a remarkable weekly performance, surging 20.49% from Rs.86.50 to Rs.104.22 between 09 and 13 February 2026, significantly outperforming the Sensex which declined by 0.54% over the same period. This strong rally was driven by a combination of positive quarterly financial results, technical upgrades, and renewed investor interest despite lingering fundamental challenges.

Key Events This Week

09 Feb: Stock opens at Rs.88.75, up 2.60% amid cautious market sentiment

10 Feb: Downgrade to Strong Sell announced, yet stock gains 1.18%

12 Feb: Technical upgrade to Sell rating announced, stock rises 3.45%

13 Feb: Positive Q4 2025 results reported, stock closes at Rs.104.22 (+6.35%)

Week Open

Rs.86.50

Week Close

Rs.104.22

+20.49%

Week High

Rs.104.22

vs Sensex

-0.54%

09 February 2026: Positive Start Despite Market Caution

The week began with Centenial Surgical Suture Ltd closing at Rs.88.75, a 2.60% gain from the previous Friday’s close of Rs.86.50. This outperformance contrasted with the Sensex’s 1.04% rise to 37,113.23, signalling early investor interest in the stock despite broader market volatility. Trading volume was modest at 42 lakh shares, reflecting cautious optimism ahead of upcoming corporate announcements.

10 February 2026: Downgrade to Strong Sell Amid Weak Fundamentals

On 10 February, MarketsMOJO downgraded Centenial Surgical Suture Ltd from 'Sell' to 'Strong Sell' citing deteriorating fundamentals and bearish technicals. The company’s Mojo Score dropped to 26.0, reflecting concerns over weak profitability, flat financial trends, and poor debt servicing capacity. Despite this negative rating, the stock price rose 1.18% to Rs.89.80, outperforming the Sensex’s modest 0.25% gain. This divergence suggests that the downgrade was already priced in or that investors were anticipating upcoming positive developments.

12 February 2026: Technical Upgrade Spurs Renewed Buying

MarketsMOJO upgraded the stock’s rating from 'Strong Sell' to 'Sell' on 12 February, driven by improved technical indicators and valuation appeal. The Mojo Score increased to 31.0, signalling cautious optimism despite persistent fundamental weaknesses. The stock responded positively, rising 3.45% to close at Rs.98.00, even as the Sensex declined 0.56% to 37,049.40. This upgrade reflected a stabilising technical outlook, with weekly MACD turning mildly bullish and monthly RSI showing improvement, suggesting a potential bottoming out of the stock’s downtrend.

13 February 2026: Strong Q4 Results Drive 6.35% Rally

Centenial Surgical Suture Ltd reported a positive financial turnaround for Q4 FY25, posting record net sales of ₹14.86 crores and profit before tax excluding other income of ₹0.15 crores. Earnings per share rose to ₹0.41, the highest quarterly figure recorded by the company. This marked a significant shift from previous flat trends, with the financial trend score improving from -3 to +6 over the last three months. The stock closed at Rs.104.22, up 6.35% on the day, outperforming the Sensex’s 1.40% decline. The intraday range of Rs.97.95 to Rs.104.22 reflected renewed investor confidence amid cautious optimism about the company’s operational momentum.

Weekly Price Performance: Stock vs Sensex

Date	Stock Price	Day Change	Sensex	Day Change
2026-02-09	Rs.88.75	+2.60%	37,113.23	+1.04%
2026-02-10	Rs.89.80	+1.18%	37,207.34	+0.25%
2026-02-11	Rs.94.73	+5.49%	37,256.72	+0.13%
2026-02-12	Rs.98.00	+3.45%	37,049.40	-0.56%
2026-02-13	Rs.104.22	+6.35%	36,532.48	-1.40%

Key Takeaways: Positive Momentum Amid Lingering Risks

Positive Signals: The week’s 20.49% price gain was fuelled by a notable financial turnaround in Q4 FY25, with record net sales and improved profitability metrics. The upgrade from 'Strong Sell' to 'Sell' on technical grounds reflected stabilising momentum and valuation appeal, encouraging renewed investor interest. The stock’s outperformance relative to the Sensex’s 0.54% decline highlights its resilience amid broader market weakness.

Cautionary Notes: Despite recent gains, fundamental challenges persist. The company’s five-year operating profit CAGR remains deeply negative at -21.26%, and return on capital employed is subdued at 2.96%. Debt servicing capacity is weak, with an EBIT to interest coverage ratio of 1.33, signalling financial vulnerability. The stock trades well below its 52-week high of Rs.189.00, indicating that the rally may be a recovery phase rather than a sustained uptrend.

Conclusion: A Week of Recovery with Fundamental Challenges Remaining

Centenial Surgical Suture Ltd’s 20.49% weekly surge represents a significant recovery driven by improved quarterly results and a technical upgrade. The stock’s outperformance against the Sensex’s decline underscores renewed investor confidence in the short term. However, the company’s weak long-term fundamentals, including poor profitability growth and low capital efficiency, temper enthusiasm. The upgrade to a 'Sell' rating from 'Strong Sell' reflects cautious optimism rather than a full turnaround. Investors should monitor upcoming financial disclosures and sector developments closely to assess whether this positive momentum can be sustained amid ongoing operational challenges.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE